Developing radionuclide PARP inhibitors – MedNous Article

Theragnositcs rPARPi (radionuclide PARP inhibitor) platform has features in the Nov-Dec issue of MedNous. Theragnostics CEO Greg Mullen describes the science behind rPARPi and the companies development of a pan-cancer therapy program.
MedNous PARPi article available here